Triple

T2138518
Position Surface form Disambiguated ID Type / Status
Subject Roche E46707 entity
Predicate product P490 FINISHED
Object Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
 E238181 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Xeloda | Statement: [Roche, product, Xeloda]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Xeloda
Context triple: [Roche, product, Xeloda]
  • A. Alimta
    Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
  • B. Avastin
    Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
  • C. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • D. Herceptin
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • E. Imbruvica
    Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Xeloda
Triple: [Roche, product, Xeloda]
Generated description
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Xeloda
Target entity description: Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
  • A. Alimta
    Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
  • B. Avastin
    Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
  • C. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • D. Herceptin
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • E. Imbruvica
    Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a88a174ab48190a5db20c132e5dccf completed March 4, 2026, 7:37 p.m.
NER Named-entity recognition batch_69abbe012aa481909ffa0a50e58efabb completed March 7, 2026, 5:56 a.m.
NED1 Entity disambiguation (via context triple) batch_69ae51b1290c8190a08850b428c99a6c completed March 9, 2026, 4:50 a.m.
NEDg Description generation batch_69ae55923b748190bf7a2df3ae94edc8 completed March 9, 2026, 5:07 a.m.
NED2 Entity disambiguation (via description) batch_69ae55fdc32c8190b6ecdc9b23d64cc5 completed March 9, 2026, 5:09 a.m.
Created at: March 4, 2026, 7:44 p.m.